Race Oncology
RAC.AXPhase 2Race Oncology is a specialty pharmaceutical company dedicated to the clinical development and commercialization of bisantrene, a drug with a unique dual mechanism of action combining DNA intercalation with inhibition of the fat mass and obesity-associated (FTO) enzyme. The company's primary focus is on acute myeloid leukemia (AML), targeting patient populations with poor prognoses, including those with relapsed/refractory disease and cardiac risk factors where bisantrene's reduced cardiotoxicity profile offers a potential advantage. Race is advancing bisantrene through clinical trials while exploring its potential in other solid and hematological malignancies. The company's strategy is built on securing intellectual property, generating robust clinical data, and pursuing strategic partnerships to maximize the value of its lead asset.
RAC.AX · Stock Price
Historical price data
AI Company Overview
Race Oncology is a specialty pharmaceutical company dedicated to the clinical development and commercialization of bisantrene, a drug with a unique dual mechanism of action combining DNA intercalation with inhibition of the fat mass and obesity-associated (FTO) enzyme. The company's primary focus is on acute myeloid leukemia (AML), targeting patient populations with poor prognoses, including those with relapsed/refractory disease and cardiac risk factors where bisantrene's reduced cardiotoxicity profile offers a potential advantage. Race is advancing bisantrene through clinical trials while exploring its potential in other solid and hematological malignancies. The company's strategy is built on securing intellectual property, generating robust clinical data, and pursuing strategic partnerships to maximize the value of its lead asset.
Technology Platform
Development of bisantrene, a dual-mechanism chemotherapeutic agent combining DNA intercalation with potent inhibition of the FTO (fat mass and obesity-associated) enzyme, a novel target in cancer epigenetics and stemness.
Pipeline Snapshot
44 drugs in pipeline
| Drug | Indication | Stage |
|---|---|---|
| Bisantrene | Acute Myelogenous Leukemia | Phase 2 |
| Bisantrene + Fludarabine + Clofarabine | Myelogenous Leukemia, Acute | Phase 2 |
| RC220 + Doxorubicin (Adriamycin) | Solid Tumours | Phase 1 |
| Bisantrene Dihydrochloride (high dose) + Bisantrene Dihydrochloride (low dose) +... | Acute Myeloid Leukemia | Phase 1 |
Funding History
3Total raised: $27M
Opportunities
Risk Factors
Competitive Landscape
Race Oncology competes in the AML space with targeted therapies (Venetoclax, FLT3/IDH inhibitors) and other chemotherapies. Its main differentiation is bisantrene's unique dual mechanism (DNA damage + FTO inhibition) and superior cardiac safety profile compared to standard anthracyclines. In the novel field of FTO inhibition, it faces potential future competition from earlier-stage biotechs.
Company Info
Trading
Contact
Therapeutic Areas
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile